Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17755394 | 0.94 | SSTR4 (0.35) | SSTR4USP30 | |
| SCHEMBL29601574 | 0.94 | SSTR4 (0.35) | SSTR4USP30 | |
| SCHEMBL22234709 | 0.80 | GAA (0.33) | SSTR4USP30 | |
| SCHEMBL24102996 | 0.74 | SSTR4 (0.38) | SSTR4BACE1 | |
| SCHEMBL799165 | 0.74 | SSTR4 (0.36) | SSTR4USP30BACE1 | |
| SCHEMBL26980538 | 0.73 | GAA (0.38) | SSTR4USP30 | |
| SCHEMBL22259343 | 0.72 | GAA (0.35) | SSTR4USP30 | |
| SCHEMBL29498379 | 0.72 | GAA (0.35) | SSTR4USP30 | |
| SCHEMBL25183270 | 0.72 | USP30 (0.36) | USP30 | |
| SCHEMBL31037785 | 0.72 | GABRG2 (0.33) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240208957-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4320110-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | Universität Basel (CH) | 2024-02-14 | — | — | EP | disclosed |
| EP-4320115-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | Universität Basel (CH) | 2024-02-14 | — | — | EP | disclosed |
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | UNIVERSITÄT BASEL (CH) | 2021-11-30 | — | — | US | disclosed |
| EP-3218358-B1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIQUR THERAPEUTICS AG (CH) | 2021-06-16 | — | — | EP | disclosed |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2020-09-03 | — | — | US | disclosed |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIQUR THERAPEUTICS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153752-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | SSTR4 2707/4885USP30 4230/4885BACE1 3827/4885 |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | SSTR4 2707/4885USP30 4230/4885BACE1 3827/4885 |
| US-20200277304-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | SSTR4 2707/4885USP30 4230/4885BACE1 3827/4885 |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | PIK3CA, MTOR, PIKFYVE | SSTR4 2707/4885USP30 4230/4885BACE1 3827/4885 |
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | PIK3R5, PIK3R1, PIK3R2 | SSTR4 4855/4885USP30 303/4885BACE1 2364/4885 |
| US-20240208957-A1 | TRIAZINE DERIVATIVE AS REVERSIBLE AND IRREVERSIBLE COVALENT INHIBITORS OF PI3K | PIK3R5, PIK3R3, PIK3R1 | SSTR4 4514/4885USP30 292/4885BACE1 3635/4885 |
| US-11186591-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIK3CA, MTOR, PIKFYVE | SSTR4 2707/4885USP30 4230/4885BACE1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.